



(51) International Patent Classification:

C07D 403/14 (2006.01) *A61P 19/02* (2006.01)
C07D 401/14 (2006.01) *A61P 19/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2014/058132

(22) International Filing Date:

29 September 2014 (29.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/884,888 30 September 2013 (30.09.2013) US

(71) Applicant: **PHARMACYCLICS, INC.** [US/US]; 995 East Arques Avenue, Sunnyvale, CA 94085 (US).

(72) Inventors: **WANG, Longcheng**; 4294 Wilkie Way, Apt. L, Palo Alto, CA 94306 (US). **CHEN, Wei**; 1668 Walden Court, Fremont, CA 94539 (US). **JIA, Zhaozhong, J.**; 3416 Leafwood Court, San Mateo, CA 94403 (US). **LOURY, David, J.**; 7130 Galli Drive, San Jose, CA 95129 (US).

(74) Agent: **HOSTETLER, Michael, J.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF BRUTON'S TYROSINE KINASE

(57) Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

